Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
8
×
deals
8
×
life sciences
national blog main
biotech
national top stories
san francisco blog main
san francisco top stories
boston blog main
new york blog main
raleigh-durham blog main
san diego blog main
seattle blog main
seattle top stories
boston top stories
detroit blog main
detroit top stories
national
new york top stories
raleigh-durham top stories
san diego top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
europe blog main
indiana blog main
indiana top stories
novartis
pfizer
roche
takeda pharmaceutical
amgen
cancer immunotherapy
covid-19
crispr
What
bio
roundup
sciences
acquisitions
buy
car
ceo
crispr
daniel
deal
drug
gilead
help
ipo
life
medicines
o’day
years
access
adding
admits
advanced
ago
aims
alliance
announced
bails
big
biggest
biotechs
brand
bridgebio
bristol
build
calls
cancer
capacity
capital
cell
changing
Language
unset
8
×
Current search:
xconomy.com
×
cancer
×
deals
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In